GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

GSK reveals steep fall in vaccine sales, backs outlook 07:13 , Graeme Evans GSK today reported a ...

GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

The pharmaceutical giant reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance ...

The FTSE 100 closed down 59.98 points at 8159.63 as traders digest Chancellor Rachel Reeves's Budget today. Among the ...

GlaxoSmithKline has announced plans to collaborate ... protein subunits, and live attenuated viruses. A digital health passport is an app, or online certification, that displays a traveller ...

A live webcast of the fireside chat can be accessed under ... Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive ...

GSK today reported a 15% drop in vaccine sales in the third quarter, offset by a 19% jump for revenues in its Speciality Medicines division. Total sales of £8 billion for the three months were 2% ...

GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.

FTSE 100 Live Wednesday GSK vaccine sale disappoint Next forecasts £1bn profit Aston Martin sticks by guidance Market update: Next and StanChart upgrades offset GSK weakness 10:10, Graeme Evans A ...